Legend Biotech (LEGN) stock

Cell therapies , market cap $4.4B

Cell therapies for oncology

Worth $4.4B

$20.41

-15.97%

As of Tuesday's close · Live for Pro members at the open

Why is LEGN down?

Down 16% on Nov 10.

Legend Biotech fell 16% that day while biotech stocks fell a median 1%: it trailed its group by 15 points.

Sources: Price history, Nov 10, 2026

Tell me next time LEGN moves

Free account, no card. An optional alert when LEGN moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →The timeline and its peers, for Pro members.

Quality Score

-2

Poor

In its industry

#162of 281

Biotech

Checks firing

2of 14

Trending down

From 52-week high

-45.6%

under its best in a year

LEGN's Quality Score fell 5 points on Tue, Nov 10, to -2. Its price fell below its average of the last 21 days (4 chart checks stopped).

Follow LEGN's trial news. Pro members can get an alert when Legend Biotech files news, and see its trials, share raises, and its CEO's filings.

Get an alert when LEGN files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2026“…when plasma cells, a type of white blood cell found in the bone marrow, become cancerous and grow. v In 2026…”Trial start · SEC filing · Sep 25

Cash$902M in cash. One of the last four quarters brought cash in while the others used it.On Dec 31 · raised money since, not counted · the company says “beyond 2026”

Key facts on LEGN

Key facts on LEGN
Long-term trend	−3 below a falling 200-day average, down over one year, down over two years, down over one year, and down over two years
Latest filing	6-K, Oct 15 Issued a release: "Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy"

1 more reason behind LEGN's -2, free with an account →2 more reasons behind LEGN's -2, for Pro members.

LEGN in the news

ReportThis morning: the results are out. Past reports ›

TodayWhat Legend Biotech (LEGN) Said on Its Q3 Earnings Call Yahoo Finance and 4 more

What's next

Sat Dec 12: American Society of Hematology…Industry event · date confirmed.

Expected to report Tue Mar 9, before the open

After its last 4 reports it closed +0.6% on average, higher 3 of 4 times.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$902M in cash. One of the last four quarters brought cash in while the others used it.On Dec 31 · raised money since, not counted · the company says “beyond 2026”

LEGN catalysts

Coming up

10 past catalysts since 2021, with sizes and sources, for Pro members.

What's next for LEGN, and how long its cash lasts

Next step the company has named

2026“…cancer that starts when plasma cells, a type of white blood cell found in the bone marrow, become cancerous and grow. v In 2026, it is estimated that more than 36,000 people will be…”Trial start · SEC filing · Sep 25

What it means: when a trial begins, or reaches the stage the company named.

A trial underway: Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction, Esophageal, or Pancreatic AdenocarcinomaPhase 1 · Active · 56 people · main data estimated Dec 2027 · NCT05539430

1 more trial, 81 filings, for Pro members.

Cash runway Dec 31, 2025 balance sheet

$902M in cash

One of the last four quarters brought cash in while the others used it, so an average says little about the next.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “beyond 2026” (8-K, Aug 11). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (F-3ASR, filed Mar 19, 2024)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Corazon (Corsee) D. Sanders sold 27,370 shares on Sep 29. 4 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Ingrid Zhang buys or sells

For Pro members: every trade, and Ingrid Zhang’s 5 filings and quotes.

Get an alert when LEGN files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How LEGN ranks in Biotech

LEGN is #162 of 281 by Quality Score.

How LEGN ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	KYTXKyverna Therapeutics		Open for its score
	LCTXLineage Cell Therapeutics		Open for its score
	LENZLENZ Therapeutics		Open for its score
	LGNDLigand Pharmaceuticals		Open for its score
162	LEGNLegend Biotech	2/14	-2

When does LEGN report earnings, and what happens after?

Expected to report Tue Mar 9, before the open (in 119 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What LEGN reported on Nov 10, 2026

The quarter

The figures are not read from the release yet.

“The increase of $91.4 million was due to an increase in revenue generated from sales of CARVYKTI ® in connection with the Janssen collaboration and license agreement (the “Janssen Agreement”).”

The filing on EDGAR

Where the sales came from

LEGN's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.

The outlook

No outlook figures read from this release.

In the company's words

“The year-over-year improvement of $91.3 million was primarily driven by improved operating income.”

From its results filing (SEC filing · Nov 10)

1 more sentence, for Pro members.

The numbers

Market value: $4.4B; today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on LEGN: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+10.5%+5.7%-16.0%

May 12Aug 11Nov 10

Reported	When	Gap	Reaction	5 days
Nov 10, 2026Before open	Before open	-12.2%	-16.0%	not yet
Aug 11, 2026Before open	Before open	+5.4%	+5.7%	-0.1%
May 12, 2026Before open	Before open	-3.7%	+10.5%	+5.5%

LEGN closed higher after 3 of its last 4 reports.

All 4 reports, and LEGN's Quality Score going into each

LEGN has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on LEGN, and all 14 on every stock.Get in free →

LEGN RSI today: 48.1, above its 50-day, below its 200-day

Not scored

RSI 48.1, MACD above signal, above its 50-day, below its 200-day. Not scored.13 readings

The deep dive on LEGN

What it does and how it makes money3 findings"We will also be eligible to receive tiered royalties from the high single digits to the low teens based upon net sales of Licensed Products, subject to certain reductions and offsets." (20-F for fiscal 2024)SEC filing · Mar 11, 2025
Where it stands1 findingFor Pro members1 finding on where LEGN stands: its cash, debt, and share count, for Pro members
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades LEGN, for Pro members
Against its closest peers2 peersFor Pro membersLEGN against 2 peers, fact by fact, for Pro members

6 more findings on LEGN, each with its source, for Pro members.

LEGN share count over time

Shares of LEGN outstanding, as filed
Shares outstanding	As of
369.9M	Dec 31, 2025
367.3M	Dec 31, 2024
363.8M	Dec 31, 2023
330.1M	Dec 31, 2022

Offerings, shelves, and splits of LEGN, from its filings
From its filings	Filed
Raised $226M in a sale of shares, about 5% of its market value	Jun 18, 2026
Registered shares for a later sale (F-3ASR)	Mar 19, 2024

LEGN insider trades

2 insiders sold $171K across 2 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellPatrick John Casey$89KDirectorat $14.80 on Jun 30, filed Jul 2

SellPatrick John CaseyDirector$89Kat $14.80 on Jun 30, filed Jul 2

LEGN's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Ying HuangChief Executive Officer · 2 trades
Alan BashInterim CEO · no trades on file
Ingrid ZhangChief Executive Officer · no trades on file
Carlos E. SantosChief Financial Officer · 1 trade
Corazon D. SandersDirector · 1 trade
Patrick John CaseyDirector · 1 trade
Darren Xiaohui JiDirector · no trades on file
Li MaoDirector · no trades on file

2 more officers and directors file at LEGN.

See insider trades by person

About Legend Biotech

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

3,200 employeeslegendbiotech.com

What Legend Biotech says it competes with

“CARVYKTI competes and any future products will compete with novel therapies developed by biopharmaceutical companies, academic research institutions, governmental agencies and public and private research institutions, in addition to standard of care treatments.”

From its annual report, SEC filing · Mar 11, 2025

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on LEGN and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn LEGN's score around: 6 things
5 more filings explained, a plain line each
2 more things pulling LEGN's score down

BreakawayJul 2Patrick John Casey sold LEGN$89K at $14.80, filed Jul 2

Alerts are optional.

See LEGN's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: LEGN's Quality Score is -2 (Poor), #162 of 281 in Biotech. Insiders sold $171K in the last 6 months (Form 4).

What does LEGN's Quality Score say?

LEGN scores -2 today, which Breakaway calls Poor. It is #162 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 16% on Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is LEGN's Quality Score?

LEGN scores -2 today, which Breakaway calls Poor (below zero). That is #162 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LEGN's -2.

Are insiders buying LEGN?

2 insiders sold $171K across 2 filings in the last 6 months. No open-⁠market buys on record. The newest is Patrick John Casey, Director, who sold $89K on Jun 30. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.